N-Hydroxyamidinoheterocycles Inhibit IDO Enzyme Activity
Solution Overview
Problem
Current treatments for IDO-related diseases such as cancer, viral infections, and autoimmune disorders lack effective modulators to inhibit tryptophan degradation, which is crucial for enhancing T-cell activation and reducing immunosuppression.
Innovation Solution
Development of compounds that modulate indoleamine 2,3-dioxygenase (IDO) activity by contacting specific compounds with IDO, thereby inhibiting its enzyme activity and altering extracellular tryptophan levels, which can be used to treat IDO-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IDO activity is up-regulated to degrade tryptophan, then antimicrobial and antiproliferative effects are achieved, but immunosuppression and T-cell response impairment occur
Solution Approach 1:
The patent applies preliminary anti-action by administering IDO inhibitors before or during immunosuppressive events to prevent the harmful immunosuppressive effects from occurring. The inhibitors are given in advance to block IDO activity before it can degrade tryptophan and suppress T-cell responses, while still allowing the antimicrobial and antitumor effects to proceed.
Solution Approach 2:
The patent converts the harmful immunosuppressive effect of IDO activity into a benefit by using IDO inhibitors to block this pathway. The same IDO enzyme that causes immunosuppression is targeted for inhibition, transforming its harmful effect into a therapeutic opportunity where blocking IDO activity enhances T-cell responses while maintaining or improving antimicrobial and antitumor efficacy.
2Object-affected harmful factors
If IDO inhibitors are administered to enhance T-cell activation, then immunosuppression is reduced, but tryptophan degradation is inhibited
Solution Approach 1:
The patent applies preliminary anti-action by pre-administering IDO inhibitors to prevent the development of immunosuppression before it occurs. The inhibitors are given in advance to block IDO activity, preventing tryptophan degradation and the subsequent suppression of T-cell responses, while still allowing antimicrobial effects to be achieved through alternative mechanisms.
Solution Approach 2:
The patent uses IDO inhibitors as intermediary substances that mediate between the conflicting needs of maintaining antimicrobial efficacy while preventing immunosuppression. These small molecule compounds act as intermediaries that selectively block IDO activity, allowing the system to achieve T-cell activation without compromising antimicrobial defense through this specific pathway.
3Adaptability or versatility
If tryptophan degradation is accelerated to suppress T-cell responses, then immune tolerance is induced, but T-cell activation is inhibited
Solution Approach 1:
The patent applies preliminary anti-action by administering IDO inhibitors to prevent tryptophan degradation before it can induce immune tolerance. The inhibitors are given in advance to block IDO activity, preventing the depletion of tryptophan that would otherwise lead to T-cell suppression, thereby maintaining T-cell activation capability while preventing inappropriate tolerance induction.
Solution Approach 2:
The patent applies inversion by reversing the natural IDO-mediated tryptophan degradation pathway. Instead of allowing IDO to degrade tryptophan and induce tolerance, the patent uses inhibitors to block this pathway, effectively doing the opposite and preventing tolerance induction while maintaining T-cell activation. This inverts the normal immunoregulatory mechanism to achieve therapeutic benefit.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit IDO activity, enhancing T-cell activation and reducing immunosuppression, providing therapeutic benefits for cancer, viral infections, and autoimmune disorders by altering tryptophan metabolism.
Implementation Method 1
The enzyme indoleamine 2,3-dioxygenase (also known as INDO or IDO) catalyzes the first and rate limiting step in the degradation of L-tryptophan to N-formyl-kynurenine. These compounds effectively inhibit IDO activity
Data Source
AI summary
The present invention is directed to N-hydroxyamidino compounds which are modulators of indoleamine 2,3-dioxygenase (IDO), as well as compositions and pharmaceutical methods thereof.